春立医疗
(688236)
| 流通市值：38.56亿 | | | 总市值：51.28亿 |
| 流通股本：2.88亿 | | | 总股本：3.84亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 417,104,217.14 | 216,972,373.23 | 1,045,766,405.34 | 756,093,897.4 |
| 营业总成本 | 286,007,552.15 | 152,107,504.3 | 722,853,785.21 | 515,865,735.32 |
| 其他经营收益 | | | | |
| 营业利润 | 135,089,659.77 | 68,048,737.03 | 302,245,079.93 | 211,727,931.57 |
| 利润总额 | 133,457,244.13 | 68,014,570.8 | 301,711,713.59 | 211,788,696.95 |
| 净利润 | 119,938,952.22 | 61,681,083.77 | 272,625,119.37 | 191,612,423.86 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 119,938,952.22 | 61,681,083.77 | 272,625,119.37 | 191,612,423.86 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,944,782,294.82 | 2,976,486,615.19 | 3,011,500,050.4 | 2,900,888,254.67 |
| 非流动资产: | | | | |
| 非流动资产合计 | 646,577,686.8 | 655,281,404.74 | 649,634,810.73 | 639,436,646.6 |
| 资产总计 | 3,591,359,981.62 | 3,631,768,019.93 | 3,661,134,861.13 | 3,540,324,901.27 |
| 流动负债: | | | | |
| 流动负债合计 | 449,872,275.76 | 488,914,115.34 | 578,602,954.95 | 458,167,274.89 |
| 非流动负债: | | | | |
| 非流动负债合计 | 91,885,039.54 | 94,180,359.37 | 95,539,444.73 | 95,917,614.15 |
| 负债合计 | 541,757,315.3 | 583,094,474.71 | 674,142,399.68 | 554,084,889.04 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,048,096,106.86 | 3,047,178,827.01 | 2,985,467,836.15 | 2,984,717,139.32 |
| 股东权益合计 | 3,049,602,666.32 | 3,048,673,545.22 | 2,986,992,461.45 | 2,986,240,012.23 |
| 负债和股东权益合计 | 3,591,359,981.62 | 3,631,768,019.93 | 3,661,134,861.13 | 3,540,324,901.27 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 393,467,990.41 | 147,928,203.2 | 1,217,975,283.51 | 805,896,136.18 |
| 经营活动现金流出小计 | 359,145,976.69 | 158,856,257.63 | 813,135,358.43 | 631,329,092.07 |
| 经营活动产生的现金流量净额 | 34,322,013.72 | -10,928,054.43 | 404,839,925.08 | 174,567,044.11 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 797,651,769.51 | - | 1,704,632,166.86 | 750,642,109.04 |
| 投资活动现金流出小计 | 752,561,388.98 | 19,994,053.2 | 1,816,327,974.35 | 930,692,401.83 |
| 投资活动产生的现金流量净额 | 45,090,380.53 | -19,994,053.2 | -111,695,807.49 | -180,050,292.79 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | - |
| 筹资活动现金流出小计 | 106,950,973.75 | 81,409,241.95 | 29,514,440.23 | 27,383,961.43 |
| 筹资活动产生的现金流量净额 | -106,950,973.75 | -81,409,241.95 | -29,514,440.23 | -27,383,961.43 |
| 汇率变动对现金及现金等价物的影响 | -537,020.27 | -320,760.32 | -174,841.04 | -248,760.77 |
| 现金及现金等价物净增加额 | -28,075,599.77 | -112,652,109.9 | 263,454,836.32 | -33,115,970.88 |
| 期末现金及现金等价物余额 | 1,374,396,887.21 | 1,289,820,377.08 | 1,402,472,486.98 | 1,105,901,679.78 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -28,075,599.77 | - | 263,454,836.32 | - |
最新报告期：2026-08-31| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华泰证券 | 代雯,孔垂岩,王殷杰 | 0.76 | 0.95 | 1.13 | 2026-08-31 |